This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
Sulphonylureas (SU) have received a terrible press in recent years. A series of publications over many years have told us that SUs increase the risk of adverse cardiovascular outcomes in diabetes patients (usually relative to metformin in observational studies),1 analyses from ACCORD and other mega...
Những tác giả chính: | Ryder, R, Holman, R, Gwilt, M |
---|---|
Định dạng: | Conference item |
Được phát hành: |
Association of British Clinical Diabetologists
2016
|
Những quyển sách tương tự
-
Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
Bằng: Holman, R, et al.
Được phát hành: (1987) -
Sulphonylureas in the management of type 2 diabetes: To be or not to be?
Bằng: André J. Scheen
Được phát hành: (2021-01-01) -
Sulphonylurea therapy over six years does not delay progression to diabetes
Bằng: Herlihy, O, et al.
Được phát hành: (2000) -
Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
Bằng: Cull, C, et al.
Được phát hành: (2000) -
Sulphonylureas and hypoglycaemia.
Bằng: Ferner, R, et al.
Được phát hành: (1988)